Lupin Announcements
Intimation about participating in the Analyst/Institutional Investors Meet.
10 Feb, 2026 | 05:12pm • Source: BSE
Settlement and License Agreement
10 Feb, 2026 | 07:44am • Source: BSE
Made in India- The story of Desh Bandhu Gupta, Lupin and Indian Pharma Book Launched in Mumbai
09 Feb, 2026 | 11:01am • Source: BSE
Lupin Launches Dasatinib Tablets in the United States.
02 Feb, 2026 | 11:14am • Source: BSE
Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Diseases.
02 Feb, 2026 | 10:11am • Source: BSE
Intimation of allotment of 169140 equity shares under ESOP.
27 Jan, 2026 | 04:26pm • Source: BSE
Lupin Receives Highest ESG Rating from CDP for Climate Change and Water Security.
23 Jan, 2026 | 12:26pm • Source: BSE
Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries.
21 Jan, 2026 | 07:52am • Source: BSE
ESG Rating by ESG Risk Assessments and Insights Limited.
19 Jan, 2026 | 04:23pm • Source: BSE
Notice of Postal Ballot dated January 06, 2026, along with Explanatory Statement.
14 Jan, 2026 | 04:56pm • Source: BSE
Appointment of Mr. Anand Kripalu as an Additional Director (Non-Executive, Independent) effective February 01, 2026 and as an Independent Director for a term of five...
06 Jan, 2026 | 09:10pm • Source: BSE
Certificate under Reg. 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended on December 31, 2025.
05 Jan, 2026 | 04:17pm • Source: BSE
Update of acquisition of VISUfarma B.V., the Netherlands.
30 Dec, 2025 | 04:29pm • Source: BSE
Lupin signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist.
29 Dec, 2025 | 06:26pm • Source: BSE
Intimation of Closure of Trading Window
26 Dec, 2025 | 03:33pm • Source: BSE
Lupin Signs Exclusive Licensing Agreement with Neopharmed for Gastroenterology Brand Plasil in the Philippines and Brazil.
18 Dec, 2025 | 03:50pm • Source: BSE
Lupin Limited has informed the Exchange regarding a press release dated December 17, 2025, titled "Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab
17 Dec, 2025 | 01:20pm • Source: NSE
Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab.
17 Dec, 2025 | 11:53am • Source: BSE
Lupin Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Lupin Secures SBTi Validation for Emission Reduction Targets
16 Dec, 2025 | 10:07am • Source: NSE
Lupin Secures SBTi Validation for Emission Reduction Targets.
16 Dec, 2025 | 10:01am • Source: BSE